Joe Luminiello is an experienced pharmaceutical and life sciences executive with nearly 30 years experience. Thought his career, Mr. Luminiello has shown superior operational, commercial and development results. My Luminiello has relevant experience in cancer, and clinical development. Most recently Mr. Luminiello served as COO for Quant HC, a start up technology our of University of Chicago and CBO for a Chicago based Accelerator.

Raymond Bergan is a physician/scientist, is Chief of Hematology/Oncology, Associate Director, Knight Cancer Institute. His group seeks to understand what causes cancer cells to move, to therapeutically inhibit that movement, and to thereby stop cancer from damaging organs and causing death.

Karl Scheidt is a Professor in the Depts. of Chemistry and Pharmacology as well as the director of Northwestern University’s Center for Drug Discovery. His laboratory develops strategies to create new molecules with translational and clinical potential.

Steven Hayes is an R&D leader with 12 years experience in life sciences and early stage drug development. He has worked in startups and large corporations. His experience includes antibody drug conjugates for oncology and novel drug screening platforms with improved predictive value.